The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two years.
MiStent was superior to the control group with a late lumen loss of 0.27 versus 0.58 (p < 0.001). No differences in MACE, cardiac death or myocardial revascularization were observed but the vessel revascularization 1.7 % for MiStent and 8.3 % for Endeavor (p = 0.04). No stent thrombosis was observed for the new device versus 1.7% for Endeavor group.
Conclusion
MiStent had significantly less late lumen loss within 2 years than zotarolimus eluting stent with permanent polymer.
William Wijns
2014-05-22
Title: DESSOLVE II trial results: 2-year follow-up of a crystalline sirolimus-eluting stent with rapid bioabsorbable polymer
